OncoTargets and Therapy · 2016 · 13 citations · 37 references
MedicineOncologyPharmacologyChemotherapyGene DeliveryMolecular OncologyApoptosis ResistanceCancer BiotechnologyPlasmid BiologyPlasmid Dna DeliveryRecombinant Plasmid ConstructionAnticancer ActivityAnticancer ChemotherapyDruggable Target DiscoveryInhibitor Of Apoptosis ProteinsPlasmid Dna VectorsPlasmid-based Gene DeliveryPromoter Activity AssaysSurvivin Inhibition
Survivin is a member of the inhibitor-of-apoptosis proteins family. It is overexpressed in many different cancer types but not in the differentiated normal tissue. In addition, overexpression of survivin promotes cancer cell survival and induces chemotherapeutic drug resistance, making it an attractive target for new anticancer interventions. Despite survivin being a promising molecular target for anticancer treatment, it is widely accepted that survivin is only a "semi-druggable" target. Therefore, it is important to develop a new strategy to target survivin for anticancer treatment. In this study, we constructed a novel survivin promoter-driven full-length antisense survivin (pSur/AS-Sur) expression plasmid DNA. Promoter activity assay revealed that the activity of the survivin promoter of pSur/AS-Sur correlated with the endogenous expression of survivin at the transcriptional level in the transfected A549, MDA-MB-231, and PANC-1 cancer cells. Western blot analysis showed that liposomal delivery of pSur/AS-Sur successfully downregulated the expression of survivin in A549, MBA-MB-231, and PANC-1 cells in vitro. In addition, delivery of pSur/AS-Sur induced autophagy, caspase-dependent apoptosis, and caspase-independent apoptosis as indicated by the increased LC3B-II conversion, autophagosome formation, caspase-9/-3 and poly(ADP-ribose) polymerase-1 cleavage, and apoptosis-inducing factor nuclear translocation in A549, MBA-MB-231, and PANC-1 cells. Importantly, liposomal delivery of pSur/AS-Sur was also capable of decreasing the proliferation of the survivin/MDR1 coexpressing multidrug-resistant KB-TAX50 cancer cells and the estrogen receptor-positive tamoxifen-resistant MCF7-TamC3 cancer cells in vitro. In conclusion, the results of this study suggest that delivery of a survivin promoter-driven antisense survivin-expressing plasmid DNA is a promising way to target survivin and to treat survivin-expressing cancers in the future.
37
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso, Yi-Mi Wu, Dan R. Robinson et al. · Nature · 2012 · 2.6K citations
Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction
Jun Hou, Joachim G.J.V. Aerts, Bianca den Hamer et al. · PLoS ONE · 2010 · 766 citations · Full text
Medicine, Cancer Biology, Oncology +17
Antisense oligonucleotides: basic concepts and mechanisms.
Nathalie Dias, C.A. Stein · PubMed · 2002 · 750 citations
FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt
Huadong Pei, Liang Li, Brooke L. Fridley et al. · Cancer Cell · 2009 · 732 citations · Full text
Medicine, Cancer Biology, Oncology +14